Hemoglobin A1c and fructosamine correlate in a patient with sickle cell disease and diabetes on chronic transfusion therapy
In patients with sickle cell disease (SCD) and diabetes mellitus (DM), hemoglobin A1c (HbA1c) is unreliable and the American Diabetes Association recommends monitoring long‐term glycemia by measuring serum glucose, but use of serum fructosamine (SF), a measurement independent of red cell lifespan, h...
Gespeichert in:
| Veröffentlicht in: | Pediatric blood & cancer 2020-09, Vol.67 (9), p.e28499-n/a |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 9 |
| container_start_page | e28499 |
| container_title | Pediatric blood & cancer |
| container_volume | 67 |
| creator | McLean, Ashley Wright, Frances deJong, Neal Skinner, Sarah Loughlin, Ceila E. Levenson, Amy Carden, Marcus A. |
| description | In patients with sickle cell disease (SCD) and diabetes mellitus (DM), hemoglobin A1c (HbA1c) is unreliable and the American Diabetes Association recommends monitoring long‐term glycemia by measuring serum glucose, but use of serum fructosamine (SF), a measurement independent of red cell lifespan, has been reported. SF as a screen for DM in SCD, however, is not standardized and its relationship to serum glucose has not been validated. Further, screening for DM was not adequately addressed in the 2014 National Heart, Lung, and Blood Institute (NHLBI) guidelines for SCD management. Blood transfusions, an important treatment for some patients with SCD, can also impact HbA1c. We present a case of a patient with SCD and cystic fibrosis‐related diabetes on monthly chronic transfusions therapy (CTT) who had well‐correlated “steady state” HbA1c and SF levels over time, suggesting for the first time these markers may actually be useful when following long‐term glycemic control in patients with SCD on CTT programs. |
| doi_str_mv | 10.1002/pbc.28499 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7674195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2428026044</sourcerecordid><originalsourceid>FETCH-LOGICAL-p2619-9e18f5d3a8f945bd1cfe58a3238f5f5e4556f485a08e4db0d132bf8030ce68953</originalsourceid><addsrcrecordid>eNpdkUFr3DAQhUVpaNK0h_4DQS-9bCJZkle-FNKlbQqB5pCcxVgeZZXakivJCUv_fLWbEGhPM8x8PN7jEfKBszPOWHM-9_as0bLrXpETrqRaKcbXr1921h2TtznfV7RlSr8hx6JpuZZcnJA_lzjFuzH2PtALbimEgbq02BIzTD4gtTElHKEgrQTQGYrHUOijL1uavf01VgTHkQ4-I2Q8CAweeiyYaQzUblMM3tKSIGS3ZF9vZYsJ5t07cuRgzPj-eZ6S229fbzaXq6uf339sLq5Wc7XZrTrk2qlBgHadVP3ArUOlQTSinp1CqVTrpFbANMqhZwMXTe80E8xiqzslTsnnJ9156SccbPWfYDRz8hOknYngzb-f4LfmLj6YdbuW_CDw6Vkgxd8L5mImn_epIWBcsmlkw7hQ1W1FP_6H3sclhRpvT-l9A1JW6vyJevQj7l6ccGb2fZrapzn0aa6_bA6L-AuIKpVx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2428026044</pqid></control><display><type>article</type><title>Hemoglobin A1c and fructosamine correlate in a patient with sickle cell disease and diabetes on chronic transfusion therapy</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>McLean, Ashley ; Wright, Frances ; deJong, Neal ; Skinner, Sarah ; Loughlin, Ceila E. ; Levenson, Amy ; Carden, Marcus A.</creator><creatorcontrib>McLean, Ashley ; Wright, Frances ; deJong, Neal ; Skinner, Sarah ; Loughlin, Ceila E. ; Levenson, Amy ; Carden, Marcus A.</creatorcontrib><description>In patients with sickle cell disease (SCD) and diabetes mellitus (DM), hemoglobin A1c (HbA1c) is unreliable and the American Diabetes Association recommends monitoring long‐term glycemia by measuring serum glucose, but use of serum fructosamine (SF), a measurement independent of red cell lifespan, has been reported. SF as a screen for DM in SCD, however, is not standardized and its relationship to serum glucose has not been validated. Further, screening for DM was not adequately addressed in the 2014 National Heart, Lung, and Blood Institute (NHLBI) guidelines for SCD management. Blood transfusions, an important treatment for some patients with SCD, can also impact HbA1c. We present a case of a patient with SCD and cystic fibrosis‐related diabetes on monthly chronic transfusions therapy (CTT) who had well‐correlated “steady state” HbA1c and SF levels over time, suggesting for the first time these markers may actually be useful when following long‐term glycemic control in patients with SCD on CTT programs.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.28499</identifier><identifier>PMID: 32618413</identifier><language>eng</language><publisher>Glenview: Wiley Subscription Services, Inc</publisher><subject>Blood glucose ; Blood transfusion ; chronic transfusion therapy ; Cystic fibrosis ; Diabetes ; Diabetes mellitus ; Hematology ; Hemoglobin ; hemoglobin A1c ; Life span ; Oncology ; Patients ; Pediatrics ; serum fructosamine ; Sickle cell disease</subject><ispartof>Pediatric blood & cancer, 2020-09, Vol.67 (9), p.e28499-n/a</ispartof><rights>2020 Wiley Periodicals LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-3860-3619</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.28499$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.28499$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids></links><search><creatorcontrib>McLean, Ashley</creatorcontrib><creatorcontrib>Wright, Frances</creatorcontrib><creatorcontrib>deJong, Neal</creatorcontrib><creatorcontrib>Skinner, Sarah</creatorcontrib><creatorcontrib>Loughlin, Ceila E.</creatorcontrib><creatorcontrib>Levenson, Amy</creatorcontrib><creatorcontrib>Carden, Marcus A.</creatorcontrib><title>Hemoglobin A1c and fructosamine correlate in a patient with sickle cell disease and diabetes on chronic transfusion therapy</title><title>Pediatric blood & cancer</title><description>In patients with sickle cell disease (SCD) and diabetes mellitus (DM), hemoglobin A1c (HbA1c) is unreliable and the American Diabetes Association recommends monitoring long‐term glycemia by measuring serum glucose, but use of serum fructosamine (SF), a measurement independent of red cell lifespan, has been reported. SF as a screen for DM in SCD, however, is not standardized and its relationship to serum glucose has not been validated. Further, screening for DM was not adequately addressed in the 2014 National Heart, Lung, and Blood Institute (NHLBI) guidelines for SCD management. Blood transfusions, an important treatment for some patients with SCD, can also impact HbA1c. We present a case of a patient with SCD and cystic fibrosis‐related diabetes on monthly chronic transfusions therapy (CTT) who had well‐correlated “steady state” HbA1c and SF levels over time, suggesting for the first time these markers may actually be useful when following long‐term glycemic control in patients with SCD on CTT programs.</description><subject>Blood glucose</subject><subject>Blood transfusion</subject><subject>chronic transfusion therapy</subject><subject>Cystic fibrosis</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Hematology</subject><subject>Hemoglobin</subject><subject>hemoglobin A1c</subject><subject>Life span</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>serum fructosamine</subject><subject>Sickle cell disease</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpdkUFr3DAQhUVpaNK0h_4DQS-9bCJZkle-FNKlbQqB5pCcxVgeZZXakivJCUv_fLWbEGhPM8x8PN7jEfKBszPOWHM-9_as0bLrXpETrqRaKcbXr1921h2TtznfV7RlSr8hx6JpuZZcnJA_lzjFuzH2PtALbimEgbq02BIzTD4gtTElHKEgrQTQGYrHUOijL1uavf01VgTHkQ4-I2Q8CAweeiyYaQzUblMM3tKSIGS3ZF9vZYsJ5t07cuRgzPj-eZ6S229fbzaXq6uf339sLq5Wc7XZrTrk2qlBgHadVP3ArUOlQTSinp1CqVTrpFbANMqhZwMXTe80E8xiqzslTsnnJ9156SccbPWfYDRz8hOknYngzb-f4LfmLj6YdbuW_CDw6Vkgxd8L5mImn_epIWBcsmlkw7hQ1W1FP_6H3sclhRpvT-l9A1JW6vyJevQj7l6ccGb2fZrapzn0aa6_bA6L-AuIKpVx</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>McLean, Ashley</creator><creator>Wright, Frances</creator><creator>deJong, Neal</creator><creator>Skinner, Sarah</creator><creator>Loughlin, Ceila E.</creator><creator>Levenson, Amy</creator><creator>Carden, Marcus A.</creator><general>Wiley Subscription Services, Inc</general><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3860-3619</orcidid></search><sort><creationdate>202009</creationdate><title>Hemoglobin A1c and fructosamine correlate in a patient with sickle cell disease and diabetes on chronic transfusion therapy</title><author>McLean, Ashley ; Wright, Frances ; deJong, Neal ; Skinner, Sarah ; Loughlin, Ceila E. ; Levenson, Amy ; Carden, Marcus A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p2619-9e18f5d3a8f945bd1cfe58a3238f5f5e4556f485a08e4db0d132bf8030ce68953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Blood glucose</topic><topic>Blood transfusion</topic><topic>chronic transfusion therapy</topic><topic>Cystic fibrosis</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Hematology</topic><topic>Hemoglobin</topic><topic>hemoglobin A1c</topic><topic>Life span</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>serum fructosamine</topic><topic>Sickle cell disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McLean, Ashley</creatorcontrib><creatorcontrib>Wright, Frances</creatorcontrib><creatorcontrib>deJong, Neal</creatorcontrib><creatorcontrib>Skinner, Sarah</creatorcontrib><creatorcontrib>Loughlin, Ceila E.</creatorcontrib><creatorcontrib>Levenson, Amy</creatorcontrib><creatorcontrib>Carden, Marcus A.</creatorcontrib><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McLean, Ashley</au><au>Wright, Frances</au><au>deJong, Neal</au><au>Skinner, Sarah</au><au>Loughlin, Ceila E.</au><au>Levenson, Amy</au><au>Carden, Marcus A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hemoglobin A1c and fructosamine correlate in a patient with sickle cell disease and diabetes on chronic transfusion therapy</atitle><jtitle>Pediatric blood & cancer</jtitle><date>2020-09</date><risdate>2020</risdate><volume>67</volume><issue>9</issue><spage>e28499</spage><epage>n/a</epage><pages>e28499-n/a</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>In patients with sickle cell disease (SCD) and diabetes mellitus (DM), hemoglobin A1c (HbA1c) is unreliable and the American Diabetes Association recommends monitoring long‐term glycemia by measuring serum glucose, but use of serum fructosamine (SF), a measurement independent of red cell lifespan, has been reported. SF as a screen for DM in SCD, however, is not standardized and its relationship to serum glucose has not been validated. Further, screening for DM was not adequately addressed in the 2014 National Heart, Lung, and Blood Institute (NHLBI) guidelines for SCD management. Blood transfusions, an important treatment for some patients with SCD, can also impact HbA1c. We present a case of a patient with SCD and cystic fibrosis‐related diabetes on monthly chronic transfusions therapy (CTT) who had well‐correlated “steady state” HbA1c and SF levels over time, suggesting for the first time these markers may actually be useful when following long‐term glycemic control in patients with SCD on CTT programs.</abstract><cop>Glenview</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32618413</pmid><doi>10.1002/pbc.28499</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-3860-3619</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2020-09, Vol.67 (9), p.e28499-n/a |
| issn | 1545-5009 1545-5017 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7674195 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Blood glucose Blood transfusion chronic transfusion therapy Cystic fibrosis Diabetes Diabetes mellitus Hematology Hemoglobin hemoglobin A1c Life span Oncology Patients Pediatrics serum fructosamine Sickle cell disease |
| title | Hemoglobin A1c and fructosamine correlate in a patient with sickle cell disease and diabetes on chronic transfusion therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A14%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hemoglobin%20A1c%20and%20fructosamine%20correlate%20in%20a%20patient%20with%20sickle%20cell%20disease%20and%20diabetes%20on%20chronic%20transfusion%20therapy&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=McLean,%20Ashley&rft.date=2020-09&rft.volume=67&rft.issue=9&rft.spage=e28499&rft.epage=n/a&rft.pages=e28499-n/a&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.28499&rft_dat=%3Cproquest_pubme%3E2428026044%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2428026044&rft_id=info:pmid/32618413&rfr_iscdi=true |